---

Cardiovascular disease causes millions of deaths worldwide, many of which could have been avoided if identified at an early stage. Consequently, the detection of cardiovascular biomarkers (cardiac troponin, cTnI, being the main target), plays a vital role in reducing mortality rates and taking appropriate precautions in good time.

While the quantification of cTnI has been described in numerous publications, highly sensitive bedside bioassays (POCT) are the next challenge for the detection of cardiac biomarkers. Field-effect transistors represent, in this context, an interesting class of devices with numerous advantages such as high sensitivity, low production cost, miniaturisation potential, etc. We have recently demonstrated the validity and sensitivity of a graphene-based field-effect transistor as a POCT option for the rapid and highly sensitive detection of cTnI, enabling the quantification of the cardiac biomarker cTnI in patient blood samples at levels that are very low or even undetectable with biological tests currently used in the clinic. Our aim is to refine cardiovascular risk stratification in patients with cardiovascular risk factors such as smoking, type 2 diabetes, dyslipidaemia and obesity, and thus improve the personalised adaptation of preventive measures and medication.

Highly performing graphene-based field effect transistor for the differentiation between mild-moderate-severe myocardial injury
By: Rodrigues, T (Rodrigues, Teresa) ; Mishyn, V (Mishyn, Vladyslav) ; Leroux, YR (Leroux, Yann R.) ; Butruille, L (Butruille, Laura) ; Woitrain, E (Woitrain, Eloise) ; Barras, A (Barras, Alexandre) ; Aspermair, P (Aspermair, Patrik) ; Happy, H (Happy, Henri) ; Kleber, C (Kleber, Christoph); Boukherroub, R (Boukherroub, Rabah); Montaigne, D (Montaigne, David); Knoll, W (Knoll, Wolfgang); Szunerits, S (Szunerits, Sabine).
http://dx.doi.org/10.1016/j.nantod.2022.101391